NCT05985083View on ClinicalTrials.gov

A Study Of IMM47 In Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

December 26, 2024

Study Completion Date

January 23, 2025

Conditions
Oncology
Interventions
DRUG

IMM47

IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.

Trial Locations (4)

2031

RECRUITING

Scientia Clinical Research Ltd, NSW, Sydney

2109

NOT_YET_RECRUITING

Macquarie University Clinical Trials Unit (MQ CTU), Sydney

4101

RECRUITING

Icon Cancer Centre South Brisbane, QLD, Brisbane

4224

NOT_YET_RECRUITING

John Flynn Private Hospital, Gold Coast

All Listed Sponsors
collaborator

IQVIA RDS Inc.

INDUSTRY

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER